LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study

Publication | Closed Access

DOI

Citations

References

2021

Year

Edward B. Garon, Melissa L. Johnson, Aaron Lisberg, Alexander I. Spira, Noboru Yamamoto, Rebecca S. Heist, Jacob Sands, Kiyotaka Yoh, Funda Meric‐Bernstam, Satoru Kitazono,

Annals of Oncology

Lba49 EfficacyActionable Genomic AlterationsMedicinePathologyPreliminary ResultsBronchial NeoplasmImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyLung CancerCancer Growth